ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Plasmodium Falciparum Malaria
Interventions
BIOLOGICAL

Malaria ICC-1132

ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.

BIOLOGICAL

Alhydrogel

Aluminum hydroxide gel.

Trial Locations (1)

21201

University of Maryland Baltimore, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00587249 - ICC-1132 - Candidate Vaccine Against P Falciparum Malaria | Biotech Hunter | Biotech Hunter